Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy Volunteers
Sponsor: Zai Lab (Shanghai) Co., Ltd.
Summary
This is a phase 1, single dose, randomized, open-label, parallel-group study to evaluate the pharmacokinetics (PK), safety, tolerability and immunogenicity of ZL-1503 and to explore its PD biomarkers following a single subcutaneous (SC) or intravenous (IV) administration in healthy volunteers.
Official title: A Phase 1, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-1503 Following a Single Dose of Subcutaneous or Intravenous Administration in Healthy Volunteers.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2026-09-03
Completion Date
2027-11-10
Last Updated
2026-08-20
Healthy Volunteers
Yes
Conditions
Interventions
ZL-1503
Healthy volunteers will receive a single intravenous dose of ZL-1503.
ZL-1503
Healthy volunteers will receive a single subcutaneous administration at Dose 1.
ZL-1503
Healthy volunteers will receive a single subcutaneous administration at Dose 2.
Locations (1)
Momentum Auckland
Takapuna, Auckland, New Zealand